Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Lilly’s bid to acquire Scorpion was driven by the Scorpion’s PI3Kα inhibitor program that is centered on the drug STX-478. The drug is in clinical studies evaluating its potential in solid tumours and ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.

The San Francisco 49ers had a dreadful season, but there were still some silver linings. Injuries decimated the 49ers' offense throughout the year, helping sink them from Super Bowl participants ...

In a significant industry move, Eli Lilly announced plans to acquire Scorpion Therapeutics' experimental cancer therapy, STX-478, for $2.5 billion. This acquisition aims to bolster Eli Lilly's cancer ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...